Apellis Pharmaceuticals, Inc. $APLS Shares Sold by Savant Capital LLC

Savant Capital LLC cut its position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) by 50.7% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 48,886 shares of the company’s stock after selling 50,297 shares during the quarter. Savant Capital LLC’s holdings in Apellis Pharmaceuticals were worth $1,106,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also added to or reduced their stakes in the company. Jones Financial Companies Lllp increased its stake in Apellis Pharmaceuticals by 206.8% during the 3rd quarter. Jones Financial Companies Lllp now owns 2,037 shares of the company’s stock worth $46,000 after buying an additional 1,373 shares during the period. Osaic Holdings Inc. grew its stake in shares of Apellis Pharmaceuticals by 141.2% during the second quarter. Osaic Holdings Inc. now owns 2,682 shares of the company’s stock valued at $47,000 after acquiring an additional 1,570 shares in the last quarter. EverSource Wealth Advisors LLC increased its position in shares of Apellis Pharmaceuticals by 338.5% during the second quarter. EverSource Wealth Advisors LLC now owns 5,429 shares of the company’s stock worth $94,000 after acquiring an additional 4,191 shares during the last quarter. Headlands Technologies LLC increased its position in shares of Apellis Pharmaceuticals by 748.8% during the second quarter. Headlands Technologies LLC now owns 6,892 shares of the company’s stock worth $119,000 after acquiring an additional 6,080 shares during the last quarter. Finally, Amalgamated Bank lifted its stake in shares of Apellis Pharmaceuticals by 12.0% in the second quarter. Amalgamated Bank now owns 8,111 shares of the company’s stock worth $140,000 after acquiring an additional 866 shares in the last quarter. 96.29% of the stock is owned by institutional investors and hedge funds.

Apellis Pharmaceuticals Price Performance

Shares of NASDAQ APLS opened at $22.58 on Wednesday. Apellis Pharmaceuticals, Inc. has a twelve month low of $16.10 and a twelve month high of $30.48. The company has a current ratio of 3.54, a quick ratio of 3.10 and a debt-to-equity ratio of 0.90. The company has a market capitalization of $2.86 billion, a price-to-earnings ratio of 72.84 and a beta of 0.26. The business has a 50 day simple moving average of $23.57 and a 200-day simple moving average of $23.86.

Insider Activity at Apellis Pharmaceuticals

In other news, CEO Cedric Francois sold 27,192 shares of Apellis Pharmaceuticals stock in a transaction dated Thursday, January 22nd. The shares were sold at an average price of $21.77, for a total value of $591,969.84. Following the completion of the transaction, the chief executive officer directly owned 286,045 shares of the company’s stock, valued at approximately $6,227,199.65. The trade was a 8.68% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Caroline Baumal sold 2,797 shares of the business’s stock in a transaction dated Thursday, January 22nd. The shares were sold at an average price of $21.77, for a total transaction of $60,890.69. Following the sale, the insider directly owned 86,527 shares of the company’s stock, valued at approximately $1,883,692.79. This represents a 3.13% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 125,169 shares of company stock valued at $2,700,681 in the last ninety days. 6.80% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on APLS shares. Barclays assumed coverage on Apellis Pharmaceuticals in a research note on Wednesday, January 28th. They set an “equal weight” rating and a $24.00 price objective for the company. TD Cowen reduced their target price on Apellis Pharmaceuticals from $50.00 to $45.00 and set a “buy” rating for the company in a research note on Friday, October 31st. Wall Street Zen raised shares of Apellis Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th. Cantor Fitzgerald cut their price target on shares of Apellis Pharmaceuticals from $39.00 to $35.00 and set an “overweight” rating on the stock in a report on Tuesday, January 13th. Finally, The Goldman Sachs Group reiterated a “sell” rating and set a $19.00 price objective on shares of Apellis Pharmaceuticals in a research note on Monday, January 12th. Twelve equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Apellis Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $33.00.

Apellis Pharmaceuticals Profile

Apellis Pharmaceuticals, Inc, traded as NASDAQ:APLS, is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the complement cascade for the treatment of rare and debilitating diseases. The company’s research and development efforts center on modulating complement proteins to address a range of ophthalmologic, hematologic and renal conditions. Apellis leverages its proprietary compstatin technology platform to design targeted inhibitors intended to improve patient outcomes and quality of life.

The company’s lead marketed product, Syfovre (pegcetacoplan), is an intravitreal complement C3 inhibitor approved for geographic atrophy secondary to age-related macular degeneration, with ongoing investigations in other retinal disorders.